Partnering & Collaborating

Accelerating the Future of

For information on partnerships, collaboration opportunities, and general licensing enquiries for Immutep, please email us at:


We are a globally active biotechnology company developing immunotherapeutic products for cancer and autoimmune diseases. Active collaborations are an integral part of our business and we have a number of collaborations underway with various corporations and academic institutions.

LAG-3 collaborations

  • eftilagimod alpha (LAG-3Ig or IMP321) is being developed in conjunction with Eddingpharm (EOC) who have licensed rights for China including Macau, Hong Kong and Taiwan. Immutep owns the rights to the rest of the world.
  • A Phase I clinical trial with a LAG-3 depleting antibody (IMP731) in autoimmune diseases with GlaxoSmithKline;
  • A Phase I/II clinical trial in immune checkpoint blockade by LAG-3 (IMP701) for cancer immunotherapy with Novartis.
  • We have other collaborations with biotech or academia, e.g. with CYTLIMIC, Japan or Monash Institute, Australia.

Collaboration and Licensing Opportunities

We welcome potential collaboration or licensing opportunities in oncology that would complement our existing portfolio and technology platform. We are also interested in novel therapeutic opportunities in other disease areas and with an immunotherapeutic background. 

If you are interested in a collaboration, licensing (in- and out-licensing) or partnership discussion we welcome you to contact us directly.


CVac therapy is a personalized immunocellular therapeutic for the treatment of epithelial cancer. The CVac treatment stimulates the patient‘s own immune system to target and destroy tumors.

In May 2016 we licensed all CVac-related assets to New York-based Sydys Corporation in exchange for a 10% shareholding in the business and potential milestone and royalty payments should CVac reach commercialization.